AKT1 and ovarian cancer: In contrast, the PI3K-Akt signaling pathway driven EMT in ovarian cancer [47] suggests evaluation of PI3K inhibitors like BKM120 or BYL719 in patients presenting with this class of tumors; Phase I clinical trials for both these molecules is underway for recurrent TNBC and HGSC [ClinicalTrials.gov Identifier: NCT01623349].